A Phase III Single Arm Study to Evaluate the Efficacy, Safety and Local Tolerability of a Subcutaneous 3-month Formulation of Triptorelin Pamoate (11.25 mg) in Patients With Locally Advanced or Metastatic Prostate Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Ipsen
- 10 Oct 2014 According to an Ipsen media release, positive results were announced at the European Association of Urology (EAU) 14th Central European Meeting in Cracow, Poland.
- 10 Oct 2014 Based on the results of this study, Ipsen has applied for the addition of the subcutaneous route, alongside the intramuscular route, to the label of triptorelin pamoate 11.25mg, according to an Ipsen media release.
- 10 Oct 2014 Results published in an Ipsen media release.